Ingalls & Snyder LLC’s Immunogen Inc IMGN Stock Holding History

Ingalls & Snyder LLC’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-11,200	Closed	-$185K	–	360
2013 Q2	$185K	Buy	+11,200	New	+$182K	0.01%	329

Other funds holding IMGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ingalls & Snyder LLC's IMGN Position: Q3 2013 in Review

Ingalls & Snyder LLC sold out of Immunogen Inc (IMGN) in Q3 2013, closing a stake of 11,200 shares — an estimated $185K sold.

Ingalls & Snyder LLC first reported a position in IMGN in Q2 2013 and held it in 1 quarter. The position peaked at $185K in Q2 2013. 141 funds tracked by Wall St. Rank hold IMGN as of Q3 2013.

Ingalls & Snyder LLC reported no remaining Immunogen Inc position as of Q3 2013 after selling out during the quarter.
Ingalls & Snyder LLC sold 11,200 Immunogen Inc shares in Q3 2013, an estimated $185K.
Ingalls & Snyder LLC first reported a position in Immunogen Inc in Q2 2013 and held it in 1 quarter.
Ingalls & Snyder LLC's Immunogen Inc position peaked at $185K in Q2 2013.
141 funds tracked by Wall St. Rank held Immunogen Inc as of Q3 2013.

Based on Ingalls & Snyder LLC's 13F filing for Q3 2013, filed 12 Nov 2013.